PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study
Abstract Background KRAS (Kirsten rat sarcoma viral oncogene homolog) gene mutation is one of the common driver gene mutations in non-small cell lung cancer (NSCLC) with poor prognosis. There are limited effective treatments for advanced NSCLC patients with KRAS mutation. This study aimed to evaluat...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2025-03-01
|
| Seri Bilgileri: | BMC Cancer |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s12885-025-13868-9 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|